ADMA Biologics (ADMA) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tarsus Pharmaceuticals (TARS) has outperformed ADMA Biologics (ADMA) over the past year, gaining 7.6% versus a loss of 27.5%. Over five years, ADMA leads with a +821.8% price change compared with +158.1% for TARS. Tarsus Pharmaceuticals is the larger company by market cap ($3.38 billion vs $2.31 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | TARS |
|---|---|---|
| Share price | $10.33 | $72.22 |
| Market cap | $2.31B | $3.38B |
| 1-day change | +1.87% | -1.89% |
| YTD return | -44.41% | -10.10% |
| 1-year return | -27.52% | +7.59% |
| 5-year return | +821.82% | +158.10% |
| P/E ratio (TTM) | 14.76 | — |
| Forward P/E | 10.95 | — |
| EPS (TTM) | $0.70 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $451.36M |
| Revenue growth (YoY) | — | +146.71% |
| Net income (latest FY) | — | $-66.42M |
| Operating margin | — | -15.72% |
| Net margin | — | -14.72% |
| 52-week high | $20.46 | $91.53 |
| 52-week low | $7.21 | $53.89 |
| Distance from 52-week high | -49.51% | -21.10% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +64.57% | +37.77% |
| Average volume | 2.63M | 894.35K |
| Shares outstanding | 223.98M | 46.79M |
| Employees | 640 | 370 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TARS has outperformed ADMA by 35.1 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
ADMA vs TARS FAQ
Which is bigger, ADMA Biologics or Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals (TARS) is larger, with a market capitalization of $3.38B compared with $2.31B for ADMA Biologics (ADMA).
Which stock has performed better over the past year, ADMA or TARS?
TARS returned +7.59% over the past 12 months, compared with -27.52% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Tarsus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.